Halozyme Therapeutics, Inc. (HALO)
Nasdaq: HALO · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2001
Grade6.8
◀ Past 7.9● Present 7.3▶ Future 5.2
Who owns Halozyme Therapeutics, Inc.
As filed with the SECHolders of 5% or more
2
Blackrock, Inc. holds 10.2% of Common Stock, as its SCHEDULE 13G/A filed Jul 17, 2025 says.
Directors and officers
14
report now, of 30 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 17, 2025 · Common Stock · 13.1% in Apr 28, 2025
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
State Street Corporation
SCHEDULE 13G · filed May 13, 2025 · COMMON STOCK · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What HALO reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Elektrofi, Inc.
A company bought · acquisition · Nov 2025 · owns, named in the 10-K filed Feb 17, 2026
Antares Pharma, Inc
A company bought · acquisition · owns, named in the 10-K filed Feb 17, 2026
Surf Bio, Inc
A company bought · asset acquisition · owns, named in the 10-K filed Feb 17, 2026
7 subsidiaries in 2 countries, from the list filed with the 10-K filed Feb 17, 2026.
Insider tradesForm 4
106sales
0purchases
102sales on a scheduled plan
5people selling
$48.4Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 8, 2025 to Oct 8, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 8, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 30 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO | 85 | $42.1M | 85 | 0 | $0 |
| Posard Matthew L. | director | 8 | $2.6M | 8 | 0 | $0 |
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER | 4 | $2.2M | 0 | 0 | $0 |
| Connaughton Bernadette | director | 8 | $800,000 | 8 | 0 | $0 |
| Krishnan Mahesh | director | 1 | $500,000 | 1 | 0 | $0 |